TScan Therapeutics (NASDAQ:TCRX) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

TScan Therapeutics (NASDAQ:TCRX) released its quarterly earnings results on Wednesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.09, FiscalAI reports. TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on equity of 73.32%. The business had revenue of $2.57 million for the quarter.

Here are the key takeaways from TScan Therapeutics’ conference call:

• Strong Phase I signals: TScan reported a 0.5 hazard ratio for relapse-free survival versus control, consistent MRD conversions to negative and detectable engineered T cells long-term, with only minimal CRS/ICANS events attributed to the product.
• Regulatory clarity and a clear development path: TScan has an FDA end-of-phase agreement on a genetically randomized pivotal trial, plans to launch in Q2, and expects a top-line readout by end of 2028, which materially de-risks the pathway to approval if results hold.
• Manufacturing advancement: a commercial-ready process shortens manufacturing from 17 to 12 days, Cohort C (10+ patients) is enrolled using that process, and Q2 data are expected to confirm comparability and support pivotal launch.
• Commercial opportunity and expansion plan: management estimates ~2,100 U.S. patients for TSC-101 (pricing example $675k → ~$1.4B peak U.S. revenue) and expansion across additional HLA types could raise the global addressable market to ~15,000 patients, but these are management projections dependent on uptake and pricing.
• Key risks remain: the Phase I dataset is small (23 treated vs 19 control), some patients still relapsed (including after additional dosing), pivotal trial size/powering is not finalized and depends on Cohort C results, so timing and outcome uncertainty remain significant.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $1.13 on Friday. The firm has a market cap of $64.13 million, a P/E ratio of -1.13 and a beta of 1.03. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.44 and a quick ratio of 6.44. TScan Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $2.57. The stock’s 50-day moving average is $1.06 and its two-hundred day moving average is $1.40.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on TCRX shares. HC Wainwright cut their target price on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Wedbush upped their price target on TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Thursday, January 22nd. Finally, Morgan Stanley downgraded TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a report on Friday, November 14th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $6.20.

Insiders Place Their Bets

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 80,069 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were purchased at an average price of $0.90 per share, with a total value of $72,062.10. Following the completion of the transaction, the insider owned 7,937,416 shares in the company, valued at $7,143,674.40. The trade was a 1.02% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have purchased a total of 161,801 shares of company stock worth $145,621 over the last 90 days. 4.35% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds have recently bought and sold shares of the business. Panagora Asset Management Inc. acquired a new stake in shares of TScan Therapeutics in the fourth quarter worth about $25,000. HRT Financial LP acquired a new stake in TScan Therapeutics in the 4th quarter worth approximately $26,000. Boothbay Fund Management LLC boosted its position in TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares during the period. Marshall Wace LLP acquired a new position in TScan Therapeutics during the second quarter valued at approximately $78,000. Finally, Voleon Capital Management LP acquired a new stake in shares of TScan Therapeutics in the third quarter worth $87,000. 82.83% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about TScan Therapeutics

Here are the key news stories impacting TScan Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near-term estimates across multiple 2026 quarters and lifted FY2026–FY2028 EPS projections (FY2026 cut from -$0.88 to -$0.76; FY2027/28 also improved) while keeping a “Buy” rating and a $7.00 price target — this signals stronger analyst confidence in TScan’s development path and is bullish for the stock. HC Wainwright research summary
• Positive Sentiment: Wedbush raised its price target to $5.00 and maintained an “Outperform” rating, providing another independent price-supportive view that can attract buyers. Wedbush / Benzinga note
• Positive Sentiment: TScan reported Q4 EPS of $(0.18), beating consensus of $(0.27) (a $0.09 beat), which can justify the upgraded analyst outlook; revenue for the quarter was $2.57M. Q4 press release
• Neutral Sentiment: HC Wainwright also published longer-term modeling (including a FY2030 EPS projection of $(0.09)), showing the firm is building a multi-year revenue/earnings roadmap — useful for estimates but not an immediate catalyst. HC Wainwright long-term estimates
• Negative Sentiment: While EPS beat, Zacks and the company’s release indicate revenue was light versus expectations (Q4 revenue $2.57M), highlighting near-term commercialization or partnering challenges that could pressure valuation if top-line growth doesn’t accelerate. Zacks article
• Negative Sentiment: HC Wainwright trimmed FY2029 EPS modestly (to $(0.49) from $(0.47)) — a small downgrade that underscores remaining execution and timeline risk for later-year forecasts. HC Wainwright estimate update

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.